Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;25(47):2001752.
doi: 10.2807/1560-7917.ES.2020.25.47.2001752.

Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020

Claudia Santos-Hövener  1   2 , Hannelore K Neuhauser  1   2 , Angelika Schaffrath Rosario  1 , Markus Busch  1 , Martin Schlaud  1 , Robert Hoffmann  1 , Antje Gößwald  1 , Carmen Koschollek  1 , Jens Hoebel  1 , Jennifer Allen  1 , Antje Haack-Erdmann  3 , Stefan Brockmann  4 , Thomas Ziese  1 , Andreas Nitsche  1 , Janine Michel  1 , Sebastian Haller  1 , Hendrik Wilking  1 , Osamah Hamouda  1 , Victor M Corman  5   6 , Christian Drosten  5   6 , Lars Schaade  1 , Lothar H Wieler  1 ; CoMoLo Study Group  7 ; Thomas Lampert  1
Collaborators, Affiliations

Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020

Claudia Santos-Hövener et al. Euro Surveill. 2020 Nov.

Abstract

Three months after a coronavirus disease (COVID-19) outbreak in Kupferzell, Germany, a population-based study (n = 2,203) found no RT-PCR-positives. IgG-ELISA seropositivity with positive virus neutralisation tests was 7.7% (95% confidence interval (CI): 6.5-9.1) and 4.3% with negative neutralisation tests. We estimate 12.0% (95% CI: 10.4-14.0%) infected adults (24.5% asymptomatic), six times more than notified. Full hotspot containment confirms the effectiveness of prompt protection measures. However, 88% naïve adults are still at high COVID-19 risk.

Keywords: COVID-19; SARS-CoV-2; antibody; seroepidemiologic studies; seroprevalence.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Dr Victor M Corman is named together with Euroimmun on a patent application filed recently regarding the diagnostic of SARS-CoV-2 by antibody testing.

Figures

Figure
Figure
Notified COVID-19 cases in adults 18 years and older and flow-chart of study design, Kupferzell, Germany, March–June 2020 (n = 5,128)
See this image and copyright information in PMC

References

    1. Santos-Hövener C, Busch MA, Koschollek C, Schlaud M, Hoebel J, Hoffmann R, et al. Seroepidemiologische Studie zur Verbreitung von SARS-CoV-2 in der Bevölkerung an besonders betroffenen Orten in Deutschland – Studienprotokoll von CORONA-MONITORING lokal. Journal of Health Monitoring. 2020;5(S5):2-18.
    1. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045. 10.2807/1560-7917.ES.2020.25.3.2000045 - DOI - PMC - PubMed
    1. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465-9. 10.1038/s41586-020-2196-x - DOI - PubMed
    1. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. Am J Epidemiol. 1978;107(1):71-6. 10.1093/oxfordjournals.aje.a112510 - DOI - PubMed
    1. Oved K, Olmer L, Shemer-Avni Y, Wolf T, Supino-Rosin L, Prajgrod G, et al. Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation. EClinicalMedicine. 2020;100651. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources